as 12-18-2024 9:52am EST
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
Upcoming Earnings Alert:
Get ready for potential market movements as Intercure Ltd. INCR prepares to release earnings report on 24 Dec 2024.
Founded: | 1994 | Country: | Israel |
Employees: | N/A | City: | N/A |
Market Cap: | 65.3M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 29.6K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.38 | EPS Growth: | N/A |
52 Week Low/High: | $1.17 - $3.72 | Next Earning Date: | 12-24-2024 |
Revenue: | $72,420,918 | Revenue Growth: | -34.26% |
Revenue Growth (this year): | -18.24% | Revenue Growth (next year): | 39.30% |
INCR Breaking Stock News: Dive into INCR Ticker-Specific Updates for Smart Investing
Market Exclusive
4 months ago
GlobeNewswire
4 months ago
MT Newswires
4 months ago
Business Wire
4 months ago
CNW Group
6 months ago
Simply Wall St.
6 months ago
AFP
6 months ago
Simply Wall St.
6 months ago
The information presented on this page, "INCR Intercure Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.